{
  "docId": "019de071-f579-76ad-bea5-b34da2c83a75",
  "docSlug": "563487226462eb4ab63630eb9b74a5cf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 42,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/25",
  "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75",
  "deckJsonHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75.json",
  "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-25",
  "components": [
    {
      "bbox": {
        "x": 0.055,
        "y": 0.77
      },
      "kind": "callout",
      "text": "The STRIDE (T300+D) regimen and durvalumab monotherapy may represent new treatment options for patients with uHCC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1c272c5-9c46-49d9-85da-4f45c007e293",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "The HIMALAYA study was a large, Phase 3 study that included a global, heterogeneous population, representative of patients with uHCC. A single priming dose of tremelimumab plus regular interval durvalumab with the STRIDE (T300+D) regimen statistically significantly improved overall survival versus sorafenib. Median overall survival was 16.4 months for STRIDE (T300+D) and 13.8 months for sorafenib. STRIDE (T300+D) appeared to provide a long-term survival benefit, with a landmark 36-month overall survival of 30.7%. Overall survival for durvalumab monotherapy was noninferior to sorafenib, with a favorable benefit-risk profile. Both STRIDE (T300+D) and durvalumab monotherapy had manageable safety profiles, with lower rates of grade 3/4 TRAEs and TRAEs leading to discontinuation than sorafenib and no increase in liver toxicity or bleeding risk",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "016cf1ea-5b74-412e-a674-74ff40202940",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.033,
        "y": 0.067
      },
      "kind": "title",
      "text": "Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8f68c23-065b-4135-8f70-7fc444b7acee",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "3c802ee2-4369-459e-8a11-aaeb34201f61",
      "evidence": "The slide presents a clear and concise key takeaway, which is a typical component of the AIDA model, aiming to grab attention, generate interest, create desire, and encourage action.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 9,
      "beatId": "5bf1753c-e4a0-4e18-b568-73af9c0043f2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents data and results for Imfinzi TOPAZ-1 and HIMALAYA, demonstrating their effectiveness",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}